MarketCapExport financials
ENDRA Life Sciences (NDRA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
ENDRA Life Sciences NDRA
$ 4.78
-0.21%
Facebook
X
Telegram
ENDRA Life Sciences Financial Ratios 2025-2011 | NDRA
Brief overview of ENDRA Life Sciences 's valuation multiples
The comparison uses the five latest available annual observations between 2021 and 2025.
The latest available valuation ratios are EV/EBITDA 0.05x (median 0.17x), P/B 1.62x (median 0.32x). The current ratio basket stands about 164.3% above the five-year base, increasing sensitivity to weak reports.
Current measures of operating quality are ROE -3.1%, ROA -182.4%, ROCE -185.7%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
On PEG (0.11x), valuation is restrained relative to growth, but one ratio cannot replace cash-flow and risk analysis.
What the ratios show
ENDRA Life Sciences 's profile looks stretched: price anticipates improvement that current quality ratios do not yet confirm.
Annual Financial Ratios ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.5 | -0.1 | -0.0 | -0.9 | -0.1 | -3.1 | -0.8 | -1.0 | -1.7 | - | - | - | - | - | - | |
P/S |
- | - | - | - | - | - | - | 1590.6 | 26.7 | - | - | - | - | - | - |
EPS |
-8.9 | -56.9 | - | -4.6 | -5.5 | -0.6 | -2.3 | -2.2 | -1.9 | -3.8 | - | - | - | - | - |
EV (Enterprise Value) |
4.49 M | -509 K | -1.74 M | 8.81 M | -6.46 M | 30.8 M | 7.48 M | 4.32 M | 4.62 M | 1.24 M | 236 K | 97.6 K | - | - | - |
EBITDA per Share |
-7.27 | -53.3 | -1.75 K | -4.12 | -5.35 | -0.59 | -1.43 | -1.92 | -1.66 | - | - | - | - | - | - |
EV/EBITDA |
-0.8 | 0.0 | 0.2 | -0.7 | 0.8 | -2.6 | -0.5 | -0.4 | -0.8 | - | - | - | - | - | - |
PEG |
-0.0 | -0.0 | -0.0 | -0.01 | - | -0.04 | 0.11 | 0.09 | 0.01 | - | - | - | - | - | - |
P/B |
1.6 | 0.3 | 0.0 | 1.6 | 0.1 | 5.1 | 2.4 | 1.6 | 1.8 | - | - | - | - | - | - |
P/CF |
-0.7 | -0.1 | -0.0 | -0.9 | -0.1 | -3.4 | -1.3 | -1.3 | -2.8 | - | - | - | - | - | - |
ROE % |
-310.93 | -449.46 | -177.77 | -182.93 | -104.14 | -163.55 | -279.50 | -156.79 | -101.92 | - | - | - | - | - | - |
ROA % |
-182.35 | -258.47 | -148.95 | -142.11 | -87.24 | -133.78 | -185.42 | -135.63 | -87.81 | - | - | - | - | - | - |
ROCE % |
-185.74 | -281.17 | -179.81 | -173.80 | -106.62 | -147.87 | -212.47 | -139.74 | -87.69 | - | - | - | - | - | - |
Current Ratio |
2.4 | 2.4 | 6.2 | 4.5 | 6.2 | 8.3 | 3.2 | 7.1 | 6.9 | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | 7.1 | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | 404.9 | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | 1648.3 | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | 412.0 | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | -1236.3 | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios ENDRA Life Sciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-1.09 | -2.1 | - | - | - | -9.54 | - | - | - | - | - | - | - | - | - | -0.07 | - | -0.06 | -0.08 | -0.06 | - | -0.15 | -0.2 | -0.29 | - | -0.46 | -0.31 | -0.37 | - | -0.7 | -0.47 | -0.72 | - | -0.23 | -0.59 | -1.03 | - | -1.35 | -1.01 | -0.52 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-1.8 | -1.79 | - | -2.59 | - | -6.07 | - | -0.25 | - | -0.37 | -0.4 | -0.92 | - | -0.05 | -0.06 | -0.07 | - | -0.06 | -0.08 | -0.07 | - | -0.13 | -0.19 | -0.27 | - | -0.35 | -0.31 | -0.37 | - | -0.59 | -0.46 | -0.72 | - | -0.22 | -0.42 | -0.48 | - | -0.77 | -0.64 | -0.49 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-1146.97 | -1109.22 | -202.77 | -194.61 | -135.48 | -195.16 | -196.41 | -237.03 | -161.98 | -195.70 | -162.95 | -157.57 | -92.17 | -112.37 | -100.00 | -85.78 | -54.26 | -99.70 | -119.86 | -144.87 | -132.16 | -203.86 | -207.45 | -224.82 | -178.48 | -222.63 | -180.48 | -176.66 | -118.92 | -136.15 | -119.14 | -103.65 | -58.43 | 50.99 | 149.79 | 219.39 | 233.45 | 109.41 | 81.58 | 42.46 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-195.75 | -178.95 | -152.54 | -149.67 | -116.98 | -116.98 | -144.64 | -167.51 | -112.66 | -140.54 | -123.21 | -121.68 | -77.46 | -94.82 | -85.50 | -74.05 | -47.92 | -108.69 | -124.35 | -143.71 | -131.70 | -179.27 | -151.02 | -156.31 | -118.40 | -156.59 | -134.59 | -141.18 | -102.88 | -117.72 | -102.91 | -89.45 | -50.33 | -249.60 | -383.32 | -437.26 | -425.15 | -199.26 | -148.57 | -77.32 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-316.02 | -255.35 | -162.11 | -176.12 | -119.72 | -177.31 | -197.67 | -238.46 | -166.13 | -199.62 | -168.82 | -157.09 | -91.76 | -111.91 | -99.77 | -87.19 | -55.70 | -97.46 | -114.31 | -134.33 | -120.12 | -171.86 | -175.67 | -192.50 | -151.13 | -188.83 | -166.27 | -166.12 | -112.29 | -129.56 | -111.89 | -89.55 | -44.14 | 23.57 | 96.14 | 157.96 | 164.79 | 67.70 | 55.31 | 41.78 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
2.1 | 1.1 | 2.1 | 2.2 | 2.4 | - | 7.2 | 3.7 | 6.2 | 3.2 | 4.0 | 3.1 | 4.5 | 5.8 | 7.8 | 5.8 | 6.2 | 7.1 | 7.7 | 18.1 | 5.5 | 2.6 | 5.5 | 5.5 | 3.0 | 3.0 | 3.0 | 3.0 | 7.4 | 7.4 | 7.4 | 7.4 | 7.2 | 7.2 | 7.2 | 7.2 | 0.3 | 0.3 | 0.3 | 0.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.6 | - | 2.2 | 10.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 147.9 | 340.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 602.0 | 1384.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.6 | - | 150.1 | 350.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.6 | - | -451.9 | -1033.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company ENDRA Life Sciences , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |  USA |
 |
Waters Corporation
WAT
|
$ 476.29 | -0.09 % | $ 28.4 B | USA |
 |
Exagen
XGN
|
$ 5.26 | -25.92 % | $ 113 M | USA |
 |
Celcuity
CELC
|
$ 67.13 | -4.11 % | $ 3.14 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 370.89 | -0.25 % | $ 30.9 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 101.65 | 0.63 % | $ 6.86 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
$ 664.97 | -1.18 % | $ 19.2 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 346.21 | -2.02 % | $ 17.2 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 750.2 | -0.69 % | $ 36.1 B |  Schweiz |
 |
Danaher Corporation
DHR
|
$ 236.19 | 0.46 % | $ 168 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 30.39 | -1.32 % | $ 28.8 B |  Niderland |
 |
RadNet
RDNT
|
$ 77.91 | -0.6 % | $ 5.86 B | USA |
 |
Senseonics Holdings
SENS
|
$ 10.05 | 2.55 % | $ 419 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | -7.8 % | $ 133 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 719.09 | -0.35 % | $ 271 B | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
$ 155.43 | -2.12 % | $ 19.5 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
$ 10.63 | -8.68 % | $ 361 M |  Israel |
 |
VolitionRx Limited
VNRX
|
$ 0.19 | -6.2 % | $ 23.9 M |  Singapore |
 |
Natera
NTRA
|
$ 311.81 | -1.92 % | $ 42.6 B | USA |
 |
IQVIA Holdings
IQV
|
$ 275.46 | -1.21 % | $ 47.4 B | USA |
 |
Agilent Technologies
A
|
$ 178.84 | -0.74 % | $ 50.8 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
DexCom
DXCM
|
$ 79.92 | -1.42 % | $ 31.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 258.38 | -0.5 % | $ 28.7 B | USA |
 |
Castle Biosciences
CSTL
|
$ 34.41 | 0.07 % | $ 997 M | USA |
 |
IDEXX Laboratories
IDXX
|
$ 696.77 | -1.4 % | $ 56 B | USA |
 |
Illumina
ILMN
|
$ 214.84 | -2.69 % | $ 33.3 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.05 | -3.48 % | $ 99 K | USA |
|
Biodesix
BDSX
|
$ 10.04 | -2.95 % | $ 75.8 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.25 | 7.66 % | $ 6.81 M | USA |
 |
Bioventus
BVS
|
$ 11.18 | 1.5 % | $ 745 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 25.83 | -1.22 % | $ 795 M | USA |
 |
CareDx, Inc
CDNA
|
$ 80.78 | -4.31 % | $ 4.3 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Britain |
 |
Biomerica
BMRA
|
$ 1.48 | -4.52 % | $ 4.31 M | USA |